Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Nawwar Al-Attar
Mitral valve repair with transcatheter techniques on a beating heart is feasible and can be effective. Approaches include direct leaflet modification, annuloplasty directly or indirectly using the coronary sinus, and ventricular geometric modification. Careful patient selection and a multidisciplinary approach are pivotal for its success and imaging techniques play a cornerstone role in the application of these procedures. Many of these devices are still in the investigational stages of development. Advances in the technology will surely improve efficacy and simplify the procedure.
Background Mitral regurgitation is the second most common type of heart valve disease in Europe and the most common type of heart valve insufficiency in the United States. Approximately 50,000 of these patients require surgical intervention each year in the United States. The incidence of mitral regurgitation is predicted to increase due to greater longevity with more degenerative and functional valve disease and patients with congestive heart failure.
The quest for a percutaneous approach is continuous despite the established feasibility, safety and results of conventional and minimally invasive surgical procedures. Emerging transcatheter techniques offer an alternative approach f patients considered high risk or contraindicated for conventional surgery. Transcatheter aortic valve implantation has already showed established feasibility in patients with severe symptomatic aortic stenosis.
Transcatheter procedures and conventional surgery alike offer techniques for mitral valve repair and percutaneous mitral valve replacement. Attempts to repair the valve have approached the problem via three distinct routes*:
This approach attempts leaflet repair by a reproduction of the edge to edge repair initially described by Alfieri . The principle is to place a suture between the leaflets to create a double orifice mitral valve by co-apting the central leaflet scallops (figure 1). In the percutaneous procedure, a guide catheter is inserted from the right femoral vein into the left atrium through a trans-septal approach. A delivery system with a clip (MitraClip®, Evalve Inc., Menlo Park, USA) (figure 2) is steered through the mitral valve and positioned under echocardiographic and fluoroscopic control until a successful result as shown by diminished mitral regurgitation is obtained. A second clip can be placed if necessary. The MitraClip® has been evaluated with the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) I which demonstrated safety and feasibility. The ongoing EVEREST II trial compares the MitraClip device with standard surgical repair or replacement. Available results,4,5 report a 85% acute procedural success, defined as a successful clip implantation with core echocardiographic laboratory assessment of MR <2+ at discharge.
Remodeling of the mitral valve by surgical mitral annuloplasty is the current standard repair technique for functional mitral regurgitation. The procedure is based on the principle of correction of leaflet coaptation by decreasing the size of the annulus. It has been performed with transcatheter techniques with devices introduced into the coronary sinus to reproduce the same effect; this has been termed“indirect annuloplasty”. It has been proposed mainly for patients with functional mitral regurgitation due to left ventricular dilatation or ischaemic papillary muscle and posterior wall dysfunction for whom surgery is not a feasible option. Several devices are available, as the Viacor percutaneous transvenous mitral annuloplasty (Viacor, Wilmington, Massachusetts, USA), CARILLON mitral contour system (Cardiac Dimensions, Kirkland, Washington, USA) and MONARC percutaneous transvenous mitral annuloplasty system (Edwards Lifesciences). The overall principal of these devices is based on a reshaping of the coronary sinus by shafts of different shapes and curves anchored proximally and distally in the coronary sinus (figure 3). Post deployment tension is applied to cinch the sinus and mitral annulus. Despite encouraging animal and preliminary human studies, there are several queries related to the real anatomical safety and applicability of this approach. Direct annuloplasty has been attempted with transcatheter techniques that emulate suture mitral annuloplasty surgery. The goal is to provide direct geometric reduction of the posterior annulus. Several systems are available such as the Mitralign Percutaneous Annuloplasty System (TM) (Mitralign, Inc. Tewksbury, MA, USA). The QuantumCor radio-frequency ablation system (QuantumCor, Lake Forest, CA, USA) attempts to reduce the annulus size of mitral valve annulus by application of radio-frequency.
The principle of these systems is to reduce mitral regurgitation by reducing the antero-posterior mitral annular diameter, re-approximating the anterior and posterior mitral valve leaflets and reducing functional mitral regurgitation. Technically speaking, they are not transcatheter devices but can be employed without the need for extracorporeal circulation. The Myocor iCoapsys (Myocor Inc., Maple Grove, MN) has been discontinued. Figure 1. The edge-to-edge repair described by Prof. Ottavio Alfieri, transforming the mitral valve into a double orifice mitral valve by co-apting the central leaflet scallops
Figure 2. The MitraClip system, consisting of V-shaped clip which is affixed to the anterior and posterior mitral leaflets
Figure 3. Cross section of the heart at the level of the atrioventricular valves. The blue line shows the site of implantation of coronary sinus devices.
Mitral valve repair with transcatheter techniques on a beating heart is feasible and can be effective. Approaches include direct leaflet modification, annuloplasty directly or indirectly using the coronary sinus, and ventricular geometric modification. Careful patient selection and a multidisciplinary approach are pivotal for its success and imaging techniques play a cornerstone role in the application of these procedures. Many of these devices are still in the investigational stages of development. Advances in the technology will surely improve efficacy and simplify the procedure. Disclosure of interest: The author has no conflict of interests. * The list of devices cited in this article is not exhaustive and is only intended for illustrative purposes.
1) Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231–43. 2) Vahanian A, Alfieri O, Al-Attar N, Antunes MJ, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr FW, Nataf P, Pierard L, Pomar JL, Schofer J, Tornos P, Tuscu M, van Hout B, von Segesser LK, Walther T. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2008; 29: 1463-70. 3) Maisano F, Caldarola A, Blasio A, et al., Midterm results of edge-to-edge mitral valve repair without annuloplasty J Thorac Cardiovasc Surg, 2003;126:1987–97. 4) Herrmann HC, Feldman T, Euro Intervention. Percutaneous mitral valve edge-to-edge repair with the Evalve MitraClip system : rationale and phase 1 results 2006;1(Suppl. A): A36–9. Feldman T, Foster E, Tunuguntla A, et al., J Am Coll Cardiol, 2007;49(Suppl. A):310A.
5) Carabello BA, Kar S, Rinaldi M, et al., Circulation, 2007;116 (Suppl. 2):357.
6) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114:e84-231. 7) Lansac E, Di Centa I, Al Attar N, Messika-Zeitoun D, Raffoul R, Vahanian A, Nataf P. Percutaneous mitral annuloplasty through the coronary sinus: an anatomic point of view. J Thorac Cardiovasc Surg. 2008;135:376-81.
Prof. N. Al-Attar practices is a cardiac surgeon at Hôpital Bichat, Paris, France. He is also web-editor of the working group on cardiovascular surgery. Disclosure of interests : The author reports no conflict of interest.